These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 27382943)

  • 1. Mitigating the burden of hepatitis C virus among people who inject drugs in Belgium.
    Matheï C; Bourgeois S; Blach S; Brixko C; Mulkay JP; Razavi H; Robaeys G
    Acta Gastroenterol Belg; 2016; 79(2):227-32. PubMed ID: 27382943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030.
    Bruggmann P; Blach S; Deltenre P; Fehr J; Kouyos R; Lavanchy D; Müllhaupt B; Rauch A; Razavi H; Schmid P; Semela D; Stoeckle M; Negro F
    Swiss Med Wkly; 2017; 147():w14543. PubMed ID: 29120012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C transmission and treatment as prevention - The role of the injecting network.
    Hellard M; McBryde E; Sacks Davis R; Rolls DA; Higgs P; Aitken C; Thompson A; Doyle J; Pattison P; Robins G
    Int J Drug Policy; 2015 Oct; 26(10):958-62. PubMed ID: 26072105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention, treatment and care of hepatitis C virus infection among people who inject drugs.
    Bruggmann P; Grebely J
    Int J Drug Policy; 2015 Feb; 26 Suppl 1():S22-6. PubMed ID: 25245939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland.
    Stone J; Martin NK; Hickman M; Hutchinson SJ; Aspinall E; Taylor A; Munro A; Dunleavy K; Peters E; Bramley P; Hayes PC; Goldberg DJ; Vickerman P
    Addiction; 2017 Jul; 112(7):1302-1314. PubMed ID: 28257600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?
    Lima VD; Rozada I; Grebely J; Hull M; Lourenco L; Nosyk B; Krajden M; Yoshida E; Wood E; Montaner JS
    PLoS One; 2015; 10(12):e0143836. PubMed ID: 26633652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland.
    Fraser H; Mukandavire C; Martin NK; Goldberg D; Palmateer N; Munro A; Taylor A; Hickman M; Hutchinson S; Vickerman P
    Addiction; 2018 Nov; 113(11):2118-2131. PubMed ID: 29781207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe.
    Fraser H; Martin NK; Brummer-Korvenkontio H; Carrieri P; Dalgard O; Dillon J; Goldberg D; Hutchinson S; Jauffret-Roustide M; Kåberg M; Matser AA; Matičič M; Midgard H; Mravcik V; Øvrehus A; Prins M; Reimer J; Robaeys G; Schulte B; van Santen DK; Zimmermann R; Vickerman P; Hickman M
    J Hepatol; 2018 Mar; 68(3):402-411. PubMed ID: 29080808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?
    Gountas I; Sypsa V; Anagnostou O; Martin N; Vickerman P; Kafetzopoulos E; Hatzakis A
    Addiction; 2017 Jul; 112(7):1290-1299. PubMed ID: 28107585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago.
    Echevarria D; Gutfraind A; Boodram B; Layden J; Ozik J; Page K; Cotler SJ; Major M; Dahari H
    Vaccine; 2019 May; 37(19):2608-2616. PubMed ID: 30962092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
    Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
    J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scaling-up HCV prevention and treatment interventions in rural United States-model projections for tackling an increasing epidemic.
    Fraser H; Zibbell J; Hoerger T; Hariri S; Vellozzi C; Martin NK; Kral AH; Hickman M; Ward JW; Vickerman P
    Addiction; 2018 Jan; 113(1):173-182. PubMed ID: 28734093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An urgent need to scale-up injecting drug harm reduction services in Tanzania: prevalence of blood-borne viruses among drug users in Temeke District, Dar-es-Salaam, 2011.
    Bowring AL; Luhmann N; Pont S; Debaulieu C; Derozier S; Asouab F; Toufik A; van Gemert C; Dietze P; Stoove M
    Int J Drug Policy; 2013 Jan; 24(1):78-81. PubMed ID: 23036650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Belgian experience with direct acting antivirals in people who inject drugs.
    Bielen R; Moreno C; Van Vlierberghe H; Bourgeois S; Mulkay JP; Vanwolleghem T; Verlinden W; Brixko C; Decaestecker J; De Galocsy C; Janssens F; Cool M; Van Overbeke L; Van Steenkiste C; D'heygere F; Cools W; Nevens F; Robaeys G
    Drug Alcohol Depend; 2017 Aug; 177():214-220. PubMed ID: 28618285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
    Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Mabileau G; Dhersin JS; Yazdanpanah Y
    J Viral Hepat; 2018 Oct; 25(10):1197-1207. PubMed ID: 29660211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals.
    Martin NK; Vickerman P; Grebely J; Hellard M; Hutchinson SJ; Lima VD; Foster GR; Dillon JF; Goldberg DJ; Dore GJ; Hickman M
    Hepatology; 2013 Nov; 58(5):1598-609. PubMed ID: 23553643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is hepatitis C virus (HCV) elimination achievable among people who inject drugs in Tijuana, Mexico? A modeling analysis.
    Marquez LK; Cepeda JA; Bórquez A; Strathdee SA; Gonzalez-Zúñiga PE; Fleiz C; Rafful C; Garfein RS; Kiene SM; Brodine S; Martin NK
    Int J Drug Policy; 2021 Feb; 88():102710. PubMed ID: 32165050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy.
    Martin NK; Hickman M; Hutchinson SJ; Goldberg DJ; Vickerman P
    Clin Infect Dis; 2013 Aug; 57 Suppl 2(Suppl 2):S39-45. PubMed ID: 23884064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact.
    Martin NK; Foster GR; Vilar J; Ryder S; Cramp ME; Gordon F; Dillon JF; Craine N; Busse H; Clements A; Hutchinson SJ; Ustianowski A; Ramsay M; Goldberg DJ; Irving W; Hope V; De Angelis D; Lyons M; Vickerman P; Hickman M
    J Viral Hepat; 2015 Apr; 22(4):399-408. PubMed ID: 25288193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study.
    Cousien A; Leclerc P; Morissette C; Bruneau J; Roy É; Tran VC; Yazdanpanah Y; Cox J
    BMC Infect Dis; 2017 Feb; 17(1):162. PubMed ID: 28222681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.